View in EDS HTML Full Text PDF Full Text

Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study.

Saved in:
Bibliographic Details
Title: Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study.
Authors: Vernieri, Fabrizio (AUTHOR), Altamura, Claudia (AUTHOR), Brunelli, Nicoletta (AUTHOR), Costa, Carmelina Maria (AUTHOR), Aurilia, Cinzia (AUTHOR), Egeo, Gabriella (AUTHOR), Fofi, Luisa (AUTHOR), Favoni, Valentina (AUTHOR), Lovati, Carlo (AUTHOR), Bertuzzo, Davide (AUTHOR), d'Onofrio, Florindo (AUTHOR), Doretti, Alberto (AUTHOR), Di Fiore, Paola (AUTHOR), Finocchi, Cinzia (AUTHOR), Schiano Di Cola, Francesca (AUTHOR), Ranieri, Angelo (AUTHOR), Colombo, Bruno (AUTHOR), Bono, Francesco (AUTHOR), Albanese, Maria (AUTHOR), Cevoli, Sabina (AUTHOR)
Source: European Journal of Neurology. Apr2022, Vol. 29 Issue 4, p1198-1208. 11p.
Subjects: Migraine aura, Primary headache disorders, Migraine, Medication abuse, Body mass index, Clinical indications, Chronically ill
Abstract: Background and purpose: A rapid response to preventive therapy is of pivotal importance in severely disabled patients with chronic migraine (CM) and diverse preventive treatment failures. This prospective, observational, multicenter real‐life study aimed at investigating the effectiveness of galcanezumab in the first 3 months of treatment of CM patients at 14 Italian headache centers. Methods: All consecutive adult patients with CM diagnosis with the clinical indication for galcanezumab were considered. We collected patients' baseline characteristics, monthly headache days, monthly painkiller intake, migraine clinical characteristics, and disability scale scores during a 1‐month run‐in period (baseline) and the first 3 months of therapy. Possible predictive factors of treatment were considered. Results: A total of 156 patients (82.4% female, aged 47.3 ± 12.3 years) were enrolled. The 65 (41.7%) patients with a consecutive ≥50% response rate (RR) in the 3 months of therapy presented a lower body mass index (p = 0.004) and more frequently presented unilateral migraine pain (p = 0.002) and good response to triptans (p = 0.003). Persistent conversion from CM to episodic migraine was observed in 55.8% (87/156) of patients. They more frequently presented a good response to triptans (p = 0.003) and unilateral pain (p = 0.046). At baseline, 131 of 156 (83.9%) patients presented medication overuse (MO). Of these, 61.8% (81/131) no longer displayed MO consistently during the 3 months. These patients were more frequently responders to triptans (p = 0.002) and less frequently suffered from gastrointestinal comorbidity (p = 0.007). Conclusions: Unilateral pain, good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab in CM patients. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 155659002
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Vernieri%2C+Fabrizio%22">Vernieri, Fabrizio</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Altamura%2C+Claudia%22">Altamura, Claudia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Brunelli%2C+Nicoletta%22">Brunelli, Nicoletta</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Costa%2C+Carmelina+Maria%22">Costa, Carmelina Maria</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aurilia%2C+Cinzia%22">Aurilia, Cinzia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Egeo%2C+Gabriella%22">Egeo, Gabriella</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fofi%2C+Luisa%22">Fofi, Luisa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Favoni%2C+Valentina%22">Favoni, Valentina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lovati%2C+Carlo%22">Lovati, Carlo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bertuzzo%2C+Davide%22">Bertuzzo, Davide</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22d'Onofrio%2C+Florindo%22">d'Onofrio, Florindo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Doretti%2C+Alberto%22">Doretti, Alberto</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Di+Fiore%2C+Paola%22">Di Fiore, Paola</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Finocchi%2C+Cinzia%22">Finocchi, Cinzia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schiano+Di+Cola%2C+Francesca%22">Schiano Di Cola, Francesca</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ranieri%2C+Angelo%22">Ranieri, Angelo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Colombo%2C+Bruno%22">Colombo, Bruno</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bono%2C+Francesco%22">Bono, Francesco</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Albanese%2C+Maria%22">Albanese, Maria</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cevoli%2C+Sabina%22">Cevoli, Sabina</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Neurology%22">European Journal of Neurology</searchLink>. Apr2022, Vol. 29 Issue 4, p1198-1208. 11p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Migraine+aura%22">Migraine aura</searchLink><br /><searchLink fieldCode="DE" term="%22Primary+headache+disorders%22">Primary headache disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Migraine%22">Migraine</searchLink><br /><searchLink fieldCode="DE" term="%22Medication+abuse%22">Medication abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Body+mass+index%22">Body mass index</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+indications%22">Clinical indications</searchLink><br /><searchLink fieldCode="DE" term="%22Chronically+ill%22">Chronically ill</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and purpose: A rapid response to preventive therapy is of pivotal importance in severely disabled patients with chronic migraine (CM) and diverse preventive treatment failures. This prospective, observational, multicenter real‐life study aimed at investigating the effectiveness of galcanezumab in the first 3 months of treatment of CM patients at 14 Italian headache centers. Methods: All consecutive adult patients with CM diagnosis with the clinical indication for galcanezumab were considered. We collected patients' baseline characteristics, monthly headache days, monthly painkiller intake, migraine clinical characteristics, and disability scale scores during a 1‐month run‐in period (baseline) and the first 3 months of therapy. Possible predictive factors of treatment were considered. Results: A total of 156 patients (82.4% female, aged 47.3 ± 12.3 years) were enrolled. The 65 (41.7%) patients with a consecutive ≥50% response rate (RR) in the 3 months of therapy presented a lower body mass index (p = 0.004) and more frequently presented unilateral migraine pain (p = 0.002) and good response to triptans (p = 0.003). Persistent conversion from CM to episodic migraine was observed in 55.8% (87/156) of patients. They more frequently presented a good response to triptans (p = 0.003) and unilateral pain (p = 0.046). At baseline, 131 of 156 (83.9%) patients presented medication overuse (MO). Of these, 61.8% (81/131) no longer displayed MO consistently during the 3 months. These patients were more frequently responders to triptans (p = 0.002) and less frequently suffered from gastrointestinal comorbidity (p = 0.007). Conclusions: Unilateral pain, good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab in CM patients. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=155659002
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ene.15197
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 1198
    Subjects:
      – SubjectFull: Migraine aura
        Type: general
      – SubjectFull: Primary headache disorders
        Type: general
      – SubjectFull: Migraine
        Type: general
      – SubjectFull: Medication abuse
        Type: general
      – SubjectFull: Body mass index
        Type: general
      – SubjectFull: Clinical indications
        Type: general
      – SubjectFull: Chronically ill
        Type: general
    Titles:
      – TitleFull: Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Vernieri, Fabrizio
      – PersonEntity:
          Name:
            NameFull: Altamura, Claudia
      – PersonEntity:
          Name:
            NameFull: Brunelli, Nicoletta
      – PersonEntity:
          Name:
            NameFull: Costa, Carmelina Maria
      – PersonEntity:
          Name:
            NameFull: Aurilia, Cinzia
      – PersonEntity:
          Name:
            NameFull: Egeo, Gabriella
      – PersonEntity:
          Name:
            NameFull: Fofi, Luisa
      – PersonEntity:
          Name:
            NameFull: Favoni, Valentina
      – PersonEntity:
          Name:
            NameFull: Lovati, Carlo
      – PersonEntity:
          Name:
            NameFull: Bertuzzo, Davide
      – PersonEntity:
          Name:
            NameFull: d'Onofrio, Florindo
      – PersonEntity:
          Name:
            NameFull: Doretti, Alberto
      – PersonEntity:
          Name:
            NameFull: Di Fiore, Paola
      – PersonEntity:
          Name:
            NameFull: Finocchi, Cinzia
      – PersonEntity:
          Name:
            NameFull: Schiano Di Cola, Francesca
      – PersonEntity:
          Name:
            NameFull: Ranieri, Angelo
      – PersonEntity:
          Name:
            NameFull: Colombo, Bruno
      – PersonEntity:
          Name:
            NameFull: Bono, Francesco
      – PersonEntity:
          Name:
            NameFull: Albanese, Maria
      – PersonEntity:
          Name:
            NameFull: Cevoli, Sabina
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: Apr2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 13515101
          Numbering:
            – Type: volume
              Value: 29
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: European Journal of Neurology
              Type: main
ResultId 1